In the present study, we investigated the endocrine status of patients with anorexia nervosa during weight loss (WL), as well as, after weight recovery (WR). A comparison between our findings and those obtained from other populations previously described was made. We studied 12 female patients during WL; 7 of them were reevaluated after WR. Stimulation tests with LRH, TRH, ACTH and insulin-induced hypoglycemia were performed in all cases. During the WL phase, basal serum levels of LH and estradiol, as well as the LH response to LRH, were diminished in comparison with normal values. Basal serum levels of FSH were low or normal. The function of the hypothalamic pituitary-ovarian axis was recovered in all patients restudied; six out of seven returned to ovulation within the first 4 months after WR. The remaining patient presented hypothalamic amenorrhea because of excessive physical activity. Four patients exhibited basal low T3 and T4 levels with normal TSH and a retarded response to TRH during WL. At WR some patients completely recovered their thyroid function while others developed clinical hypothyroidism. Six months after WR all patients were euthyroid. Prolactin response to TRH was unaffected in 10 patients. One patient had basal hyperprolactinemia and hyperesponsiveness to TRH, and the remaining one had only a PRL hyperesponsiveness; this latter finding persisted in one of these patients during the WR phase. This abnormality was attributed to changes in the dopaminergic tone secondary to stress. Although serum growth hormone concentrations were normal in all patients during WL, two of them had basal hypersecretion and hyperesponsiveness to hypoglycemia during WR, which was attributed to protein deficiency.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
---|
Int J Pediatr Otorhinolaryngol
January 2025
Otorhinolaryngology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt; Medicine and Surgery Program, Menoufia National University, Menoufia, Egypt. Electronic address:
Purpose: Familial Mediterranean fever (FMF) is the most prevalent genetic autoinflammatory disease worldwide. There are several novel advancements in pathophysiology, genetic testing, diagnosis, comorbidities, disease-related damage, and treatment strategies. This study aimed to assess the effect of tonsillectomy on FMF disease severity and activity.
View Article and Find Full Text PDFEur J Med Chem
January 2025
School of Pharmaceutical Sciences, Guizhou University, Guiyang, 550025, China. Electronic address:
Temozolomide, a widely used alkylating agent for glioblastoma treatment, faces significant challenges due to the development of resistance, which severely impacts patient survival. This underscores the urgent need for novel strategies to overcome this barrier. Focal adhesion kinase (FAK), an intracellular non-receptor tyrosine kinase, is highly expressed in glioblastoma cells and has been identified as a promising therapeutic target for anti-glioblastoma drug development.
View Article and Find Full Text PDFBiomed Phys Eng Express
January 2025
F. Joseph Halcomb III, MD, Department of Biomedical Engineering, University of Kentucky, 143 Graham Ave., Lexington, Kentucky, 40506, UNITED STATES.
Brain-computer interfaces (BCIs) offer disabled individuals the means to interact with devices by decoding the electroencephalogram (EEG). However, decoding intent in fine motor tasks can be challenging, especially in stroke survivors with cortical lesions. Here, we attempt to decode graded finger extension from the EEG in stroke patients with left-hand paresis and healthy controls.
View Article and Find Full Text PDFAnn Intern Med
January 2025
Department of Neurology, Stanford University, Palo Alto, California.
Ann Intern Med
January 2025
Durham VA Health Care System, Durham; and Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina (K.M.G.).
Background: Tissue-based genomic classifiers (GCs) have been developed to improve prostate cancer (PCa) risk assessment and treatment recommendations.
Purpose: To summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris GCs on risk stratification and patient-clinician decisions on treatment choice among patients with localized PCa considering first-line treatment.
Data Sources: MEDLINE, EMBASE, and Web of Science published from January 2010 to August 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!